FDA-cleared profile

CardIQ Suite

GE Medical Systems SCS · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Cardiac CT visualization, measurement, segmentation, tracking, labeling, and calcium scoring to support review of cardiovascular anatomy and pathology, coronary artery disease, and treatment-path decisions.

Clinical role
Interactive cardiac CT visualization, segmentation, centerline tracking, labeling, measurement, and calcium-scoring aid with manual editing and clinician interpretation.
Images and patients
CT/CTA · Heart and cardiovascular structures, including coronaries, chambers, vessels, valves, and aorta
Key limitation
Keep in mind: The output is an aid to clinician review and does not replace clinical judgment. Users can edit automated segmentations, tracking, labeling, and calcium scores. The FDA reader study reports acceptability for good-quality exams but does not establish a single diagnostic performance metric or current commercial compatibility.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Cardiac CT visualization, measurement, segmentation, tracking, labeling, and calcium scoring to support review of cardiovascular anatomy and pathology, coronary artery disease, and treatment-path decisions.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Heart and cardiovascular structures, including coronaries, chambers, vessels, valves, and aorta Input: 2D or 3D cardiac non-contrast CT and angiography DICOM data from acquisitions of the heart.
  • Who uses it?Intended users: Clinicians interpreting cardiac CT and cardiovascular findings; the FDA packet does not narrow the user population further.
  • What does the software produce?Output: Automatic and manual measurements; heart and coronary segmentation, centerline tracking, and labeling; coronary calcium scores using AJ 130, volume, and adaptive-volume methods; calcium previews and cardiac review tools; and DICOM SR export of calcium-scoring results.
  • What is its most important limitation?Key limitation: The output is an aid to clinician review and does not replace clinical judgment. Users can edit automated segmentations, tracking, labeling, and calcium scores. The FDA reader study reports acceptability for good-quality exams but does not establish a single diagnostic performance metric or current commercial compatibility.

Clinical takeaway. Clinical role: Cardiac CT visualization, measurement, segmentation, tracking, labeling, and calcium scoring to support review of cardiovascular anatomy and pathology, coronary artery disease, and treatment-path decisions.

Evidence takeaway. Evidence from the reviewed source record: FDA design-control and engineering validation covered four introduced algorithms for heart segmentation, coronary-tree segmentation, coronary-centerline tracking, and coronary labeling. A reader study evaluated these automated outputs on clinical CT images using Likert and additional grading scales; readers rated the outputs acceptable in more than 90% of exams with good image quality. The reviewed FDA summary does not state the reader-study sample size, site count, reference standard, or standalone sensitivity and specificity.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Cardiac CT visualization, measurement, segmentation, tracking, labeling, and calcium scoring to support review of cardiovascular anatomy and pathology, coronary artery disease, and treatment-path decisions.
  • Exact FDA submission
  • Checked 2026-09-08
Workflow role
Interactive cardiac CT visualization, segmentation, centerline tracking, labeling, measurement, and calcium-scoring aid with manual editing and clinician interpretation.
  • Exact FDA submission
  • Checked 2026-09-08
Required input
2D or 3D cardiac non-contrast CT and angiography DICOM data from acquisitions of the heart.
  • Exact FDA submission
  • Checked 2026-09-08
Output and clinician action
Automatic and manual measurements; heart and coronary segmentation, centerline tracking, and labeling; coronary calcium scores using AJ 130, volume, and adaptive-volume methods; calcium previews and cardiac review tools; and DICOM SR export of calcium-scoring results.
  • Exact FDA submission
  • Checked 2026-09-08
Care setting
Cardiac CT review and reporting workflow.
  • Exact FDA submission
  • Checked 2026-09-08
Intended users
Clinicians interpreting cardiac CT and cardiovascular findings; the FDA packet does not narrow the user population further.
  • Exact FDA submission
  • Checked 2026-09-08
Limitations
The output is an aid to clinician review and does not replace clinical judgment. Users can edit automated segmentations, tracking, labeling, and calcium scores. The FDA reader study reports acceptability for good-quality exams but does not establish a single diagnostic performance metric or current commercial compatibility.
  • Exact FDA submission
  • Checked 2026-09-08
Evidence summary
FDA design-control and engineering validation covered four introduced algorithms for heart segmentation, coronary-tree segmentation, coronary-centerline tracking, and coronary labeling. A reader study evaluated these automated outputs on clinical CT images using Likert and additional grading scales; readers rated the outputs acceptable in more than 90% of exams with good image quality. The reviewed FDA summary does not state the reader-study sample size, site count, reference standard, or standalone sensitivity and specificity.
  • Exact FDA submission
  • Checked 2026-09-08

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA design-control and engineering validation covered four introduced algorithms for heart segmentation, coronary-tree segmentation, coronary-centerline tracking, and coronary labeling. A reader study evaluated these automated outputs on clinical CT images using Likert and additional grading scales; readers rated the outputs acceptable in more than 90% of exams with good image quality. The reviewed FDA summary does not state the reader-study sample size, site count, reference standard, or standalone sensitivity and specificity.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

CardIQ Suite regulatory performance study summary

  • DesignReader Study
  • PopulationPopulation described in the exact-submission ACR model card
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K233731
  • IndependenceIndependence not established

K233731

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K233731. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-08
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: 2D or 3D cardiac non-contrast CT and angiography DICOM data from acquisitions of the heart.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-08 · FDA K233731: CardIQ Suite

  2. Routing

    Source context, not route validation: Works with DICOM CT data on the AW Server platform, exports calcium results as DICOM SR, and can save or export images; exact current PACS, RIS, EHR interfaces, versions, and deployment model are not established.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-08 · FDA K233731: CardIQ Suite

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. A legacy catalog deployment category, normalized to fixed categories, was not traced to the exact FDA decision document it cited, so it is not published as verified. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor or an exact-submission source that states it.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-13 ·

  4. Returned objects

    Source context, not route validation: Automatic and manual measurements; heart and coronary segmentation, centerline tracking, and labeling; coronary calcium scores using AJ 130, volume, and adaptive-volume methods; calcium previews and cardiac review tools; and DICOM SR export of calcium-scoring results.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-08 · FDA K233731: CardIQ Suite

  5. Viewer/worklist/report

    Unresolved route: Automatic and manual measurements; heart and coronary segmentation, centerline tracking, and labeling; coronary calcium scores using AJ 130, volume, and adaptive-volume methods; calcium previews and cardiac review tools; and DICOM SR export of calcium-scoring results.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-08 · FDA K233731: CardIQ Suite

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
Works with DICOM CT data on the AW Server platform, exports calcium results as DICOM SR, and can save or export images; exact current PACS, RIS, EHR interfaces, versions, and deployment model are not established.
  • Exact FDA submission
  • Checked 2026-09-08

Input or output interoperability

DICOM is explicitly referenced in the described input, output, or workflow.

exact submission · checked 2026-09-01

The model card does not establish every supported DICOM object, transfer method, or local interface.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for CardIQ Suite; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-08
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K233731
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Anatomy
Heart and cardiovascular structures, including coronaries, chambers, vessels, valves, and aorta
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2024-08-01
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
22Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission

    No public price or quote for the exact K233731 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Deployment: Not verified - checked 2026-11-13 - Exact FDA submission

    A legacy catalog deployment category, normalized to fixed categories, was not traced to the exact FDA decision document it cited, so it is not published as verified. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor or an exact-submission source that states it.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-08 - Exact FDA submission

    Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-08 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

7 sources - 3 history items

Source ledger

  1. FDA K233731: CardIQ Suite

    U.S. Food and Drug Administration - Published 2024-08-01 - Accessed 2026-09-08

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. CardIQ Suite model card (K233731)

    American College of Radiology - Published 2026-06-26 - Accessed 2026-09-01

    Scope: intendedUsers, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K233731

    U.S. Food and Drug Administration - Accessed 2026-09-08

    Scope: postmarketSafety

Research history

  1. K233731 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K252029

AI-CVD

HeartLung Corporation

Authorized purpose: AI-CVD provides automated quantitative CT-derived anatomical and density measurements for clinician review, including calcium scores, cardiac and vascular measurements, lung and liver density, bone mineral density, and muscle/fat composition; it is opportunistic decision support, not diagnostic interpretation or risk prediction.

Modality
CT/CTA
Anatomy
Chest, abdomen, heart, lungs, liver, aorta, pulmonary artery, bone, muscle, and fat
Decision
2025-12-19
FDA-cleared K252217

CT VScore+

Canon Medical Informatics, Inc.

Authorized purpose: CT VScore+ evaluates calcified coronary lesions on ECG-gated, non-contrast cardiac CT in patients aged 30 years or older, automatically generating coronary calcium scores and highlighted calcium segmentation for qualified clinical review.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-11-28
FDA-cleared K251027

cvi42 Coronary Plaque Software Application

Circle Cardiovascular Imaging, Inc.

Authorized purpose: cvi42 Coronary Plaque supports qualified professionals with viewing, post-processing, and qualitative and quantitative evaluation of adult cardiac CT DICOM images to assess the presence and extent of coronary plaques and stenoses in CCTA for CAD or suspected CAD.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-10-27

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history